MedinCell Revenue

MedinCell had revenue of 14.15M EUR in the half year ending September 30, 2025, with 72.95% growth. This brings the company's revenue in the last twelve months to 32.44M, up 145.75% year-over-year. In the fiscal year ending March 31, 2025, MedinCell had annual revenue of 27.73M with 132.12% growth.

Revenue (ttm)

32.44M

Revenue Growth

+145.75%

P/S Ratio

23.60

Revenue / Employee

223.72K

Employees

145

Market Cap

765.49M

Revenue Chart

Revenue History

Fiscal Year End	Revenue	Change	Growth
Mar 31, 2025	27.73M	15.78M	132.12%
Mar 31, 2024	11.95M	-1.71M	-12.52%
Mar 31, 2023	13.66M	5.32M	63.77%
Mar 31, 2022	8.34M	152.00K	1.86%
Mar 31, 2021	8.19M	2.19M	36.43%
Mar 31, 2020	Pro	Pro	Pro
Mar 31, 2019	Pro	Pro	Pro
Mar 31, 2018	Pro	Pro	Pro
Mar 31, 2017	Pro	Pro	Pro
Mar 31, 2016	Pro	Pro	Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name	Revenue
Valneva SE	179.91M
Inventiva	16.97M
DBV Technologies	4.69M
Genfit	45.13M
Nanobiotix	10.16M
Cellectis	70.36M
Transgene	7.58M
Innate Pharma	12.64M

Revenue Rankings

MedinCell News

16 days ago - Teva, Medincell granted FDA review for long-acting antipsychotic - Seeking Alpha
16 days ago - FDA Accepts NDA For Teva And Medincell's Olanzapine LAI In Schizophrenia Treatment - Nasdaq
5 months ago - Teva : FDA Grants Expanded Approval For UZEDY To Treat Bipolar I Disorder In Adults - Nasdaq
6 months ago - Medincell Reports Positive Phase 3 Safety Data For Olanzapine LAI; No PDSS Observed - Nasdaq
1 year ago - Teva Pharmaceuticals reports completion of phase 3 trial for Olanzapine LAI in Schizophrenia - Seeking Alpha

More News